In Vitro Activity of Fluconazole and Voriconazole Against More Than 10000 Yeast Strains: Results of 5-years Prospective ARTEMIS Disk Study in Russia

Clinical Microbiology and Antimicrobial Chemotherapy. 2008; 10(4):345-354

​ Veselov A.V., Klimko N.N., Krechikova O.I., Klyasova G.A., Agapova E.D., Multyh I.G., Rozanova S.M., Krainova L.E., Dmitrieva N.V., Kozlov R.S.
Candida spp candidiasis fluconazole voriconazole susceptibility disk-diffusion method
Section
Antimicrobial Resistance
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2008; 10(4):345-354

Purpose of the study.

From 2003 till 2008 eight research centers in Russia from Ekaterinburg, Irkutsk, Krasnodar, Novosibirsk, Moscow, St. Petersburg and Smolensk took part in ARTEMIS Disk study, the main purpose of which was the monitoring of epidemiology of candidiasis causative agents and resistance of the clinically significant

Results.

A total of 10,652 strains were tested during the period of 5 years. The main sources of clinical material were: genital (36.6%), upper respiratory tract (20.3%), lower respiratory tract (12.0%), lower gastrointestinal tract (10.8%), and urinary tract (7.6%). The predominant species were: C. albicans (76.1%), C. glabrata (5.3%), Candida spp. (3.8%), C. krusei (3.4%) and C. parapsilosis (3.1%). C. albicans shows high in vitro susceptibility both to fluconazole (95.9% of susceptible strains) and voriconazole (96.0% of susceptible strains). The lowest activity of fluconazole noted for C. krusei (9.5% of susceptible strains) and C. glabrata (59.3% of susceptible strains). Voriconazole was highly active against all Candida species with the least activity against C. glabrata (74.2% of susceptible strains). Among fluconazole-resistant strains the highest activity of voriconazole was noted against C. krusei (84.4% of susceptible strains) and C. parapsilosis (78.6% of susceptible strains).

Conclusions.

Fluconazole retains activity against all Candida species except C. krusei и C. glabrata. Voriconazole is highly activity against all Candida species, except C. glabrata, but including the majority of fluconazole-resistant strains.

  • 1. Alexander B.D., Pfaller M.A. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis 2006; 43:S15-S27.
  • 2. Fridkin S.K. The changing face of fungal infections in health care settings. Clin Infect Dis 2005; 41:1455-60.
  • 3. Pfaller M.A., Diekema D.J. Rare and emerging opportunistic fungal pathogens: concerns for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42:4419-31.
  • 4. Walsh T.J., Groll A., Hiemenz J., et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10(Suppl. 1):48-66.
  • 5. Pfaller M.A., Diekema D.J. The epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20:133-63.
  • 6. Spellberg B.J., Filler S.G., Edwards J.E. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42:244-51.
  • 7. Spanakis E.K., Aperis G., Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006; 43:1060-8.
  • 8. Walsh T.J., Groll A., Hiemenz J., et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10(Suppl. 1):48- 66.
  • 9. Meis J., Petrou M., Bille J., and the Global Antifungal Surveillance Group. A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagn Microbiol Infect Dis 2000; 36:215-23.
  • 10. Hazen K.C., Baron E.J., Colombo A.L., and the Global Antifungal Surveillance Group. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J Clin Microbiol 2003; 41:5623-32.
  • 11. Pfaller M.A., Diekema D.J., Rinaldi M., and the Global Antifungal Surveillance Group. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005; 43:5848-59.
  • 12. National Committee for Clinical Laboratory Standards. 2004. Method for antifungal disk diffusion susceptibility testing of yeasts: approved guidance M44-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  • 13. CLSI. 2005. Minutes of the CLSI Antifungal Subcommittee Meeting, 2005. CLSI, Wayne, Pa.
  • 14. Data available from www.biomic.com.
  • 15. Веселов А.В., Страчунский Л.С., Мултых И.Г. и соавт. Эпидемиология возбудителей кандидозов и их чувствительность к азолам: результаты исследования ARTEMIS Disk в России. Клин микробиол антимикроб химиотер 2005; 7:25-33.
  • 16. Pfaller M.A., Diekema D.J., Gibbs D.L., et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007; 45:1735-45.
  • 17. Chen A., Sobel J. Emerging azole antifungals. Expert Opin Emerg Drugs 2005; 10:21-33.
  • 18. Magill S.S., Shields C., Sears C., et al. Triazole crossresistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006; 44:529-35.
  • 19. Panackal A.A., Gribskov J.L., Staab J.F., et al. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006; 44:1740-3.
  • 20. Pappas P.G., Rex J.H., Sobel J.D., et al. for the Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38:161-89.
  • 21. Pfaller M.A., Jones R.N. for the Microbiology Resource Committee of the College of American Pathologists. Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists (CAP) Microbiology Surveys Program (2001–2003). Arch Pathol Lab Med 2006; 130:767-78.
  • 22. Pfaller M.A., Messer S.A., Boyken L., et al. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. tested by Clinical and Laboratory Standards Institute-recommended broth microdilution methods. J Clin Microbiol 2007; 45:70-5.
  • 23. Pfaller M.A., Diekema D.J., Procop G.W., Rinaldi M.G. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J Clin Microbiol 2007; 45:796-802.
  • 24. Rex J.H., Pfaller M.A. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002; 35:982-9.
  • 25. Rex J.H., Pfaller M.A., Walsh T.J., et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14:643-58.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared